<?xml version="1.0" encoding="UTF-8"?>
<akn:akomaNtoso xmlns:akn="http://docs.oasis-open.org/legaldocml/ns/akn/3.0">
  <akn:act name="dc-code">
    <akn:meta>
      <akn:identification source="#cosilico">
        <akn:FRBRWork>
          <akn:FRBRuri value="/akn/us-dc/code/48-844.03"/>
          <akn:FRBRdate date="2025-12-31" name="retrieval"/>
          <akn:FRBRauthor href="#dc-council"/>
          <akn:FRBRcountry value="us-dc"/>
        </akn:FRBRWork>
        <akn:FRBRExpression>
          <akn:FRBRuri value="/akn/us-dc/code/48-844.03/eng@2025"/>
          <akn:FRBRdate date="2025-12-31"/>
          <akn:FRBRauthor href="#cosilico"/>
          <akn:FRBRlanguage language="en"/>
        </akn:FRBRExpression>
      </akn:identification>
    </akn:meta>
    <akn:body>
      <akn:section eId="sec_48_844_03">
        <akn:num>48-844.03</akn:num>
        <akn:heading>Evaluation.</akn:heading>
<akn:subsection eId="subsec_48-844_03_a">
      <akn:num>(a)</akn:num>
      <akn:content><akn:p>Within 60 days of September 30, 2010, the Department of Health shall submit to the Council a comprehensive evaluation on the effectiveness of the SafeRx Amendment Act of 2008, effective March 26, 2008 (D.C. Law 17-131), which shall include:</akn:p></akn:content>
    </akn:subsection><akn:subsection eId="subsec_48-844_03_b">
      <akn:num>(b)</akn:num>
      <akn:content><akn:p>The evaluation may be used to determine if D.C. Law 17-131 should be repealed or amended.</akn:p></akn:content>
    </akn:subsection>
      </akn:section>
    </akn:body>
  </akn:act>
</akn:akomaNtoso>
